NovAccess Global (OTCQB: XSNX)

ABOUT: NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics and is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors. They offer a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Their patented technology is designed to combine a dendritic cell-based immunotherapeutic approach to help promote an enhanced immune response against the patient’s tumor. For more information, please visit novaccessglobal.com.

Interview with Dwain Morris-Irvin, CEO

THIS INTERVIEW HAS EXPIRED

About The Wall Street Analyzer 1245 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.

Be the first to comment

Leave a Reply